Analytical Data
-
Gene name
Ifna11
- Application
-
Alternative Names
Ifna11；Interferon alpha-11
-
Species
Mouse
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q61716
-
Expression Region
24-190aa
-
AA Sequence
CDLPHTY NLRNKRALKV LAQMRRLSPL SCLKDRQDFG FPLEKVDAQQ IKKAQAIPVL RDLTQQILNL FTSKASSAAW NATLLDSFCN DLHQQLNDLQ GCLMQQVGVQ EPPLTQEDAL LAVRIYFHSI TVFLREKKHS PCAWEVVRAE VWRALSSSVN LLARLSEEKA
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFNA11, a member of the interferon-alpha family, plays a crucial role in the immune response against viral infections and in modulating immune system activity. This protein is produced by a variety of cells, particularly in response to viral stimuli, leading to the activation of antiviral pathways and the enhancement of immune surveillance. Research on the recombinant form of IFNA11 has gained momentum due to its potential therapeutic applications, including the treatment of viral infections, certain cancers, and autoimmune diseases. The understanding of IFNA11's structure-function relationship is essential for developing effective therapeutic agents, making the production of recombinant IFNA11 a focal point in biotechnology. Previous studies have highlighted its ability to induce the expression of genes that encode proteins involved in apoptosis, cell growth inhibition, and immunomodulation. The production and purification of recombinant IFNA11 not only allow for in-depth functional studies but also pave the way for clinical applications. Investigating its efficacy and safety in different therapeutic contexts is vital for harnessing its full potential, thereby contributing to the advancement of antiviral therapies and cancer immunotherapy. Overall, research on IFNA11 represents a significant intersection of molecular biology, immunology, and therapeutic development, aiming to improve patient outcomes through innovative treatment approaches.
